Supernus Pharma Financials
This page shows Supernus Pharma (SUPN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
High gross-profit economics were overwhelmed in FY2025 by a surge in selling costs, not by weaker product-level profitability.
From FY2024 to FY2025, gross margin expanded from88.2% to89.6% , so the earnings break did not start at the product level. Instead, SG&A inflation and heavier working-capital needs pulled results down: operating income swung from$81.7M to-$62.3M as receivables and inventory rose, which also left operating cash flow much thinner.
Earnings are more volatile than cash because depreciation and amortization stayed between
Capital intensity is low: capital spending was just
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Supernus Pharma's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Supernus Pharma has an operating margin of -8.7%, meaning the company retains $-9 of operating profit per $100 of revenue. This results in a moderate score of 31/100, indicating healthy but not exceptional operating efficiency. This is down from 12.3% the prior year.
Supernus Pharma's revenue grew 8.6% year-over-year to $719.0M, a solid pace of expansion. This earns a growth score of 62/100.
Supernus Pharma carries a low D/E ratio of 0.37, meaning only $0.37 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 65/100, indicating a strong balance sheet with room for future borrowing.
Supernus Pharma's current ratio of 1.90 indicates adequate short-term liquidity, earning a score of 55/100. The company can meet its near-term obligations, though with limited headroom.
Supernus Pharma converts 6.4% of revenue into free cash flow ($46.0M). This strong cash generation earns a score of 78/100.
Supernus Pharma's ROE of -3.6% shows moderate profitability relative to equity, earning a score of 30/100. This is down from 7.1% the prior year.
Supernus Pharma scores 5.45, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.8B) relative to total liabilities ($390.9M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Supernus Pharma passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Supernus Pharma generates $-1.23 in operating cash flow ($47.3M OCF vs -$38.6M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Key Financial Metrics
Earnings & Revenue
Supernus Pharma generated $719.0M in revenue in fiscal year 2025. This represents an increase of 8.6% from the prior year.
Supernus Pharma's EBITDA was $29.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 81.9% from the prior year.
Supernus Pharma reported -$38.6M in net income in fiscal year 2025. This represents a decrease of 152.2% from the prior year.
Supernus Pharma earned $-0.68 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 151.5% from the prior year.
Cash & Balance Sheet
Supernus Pharma generated $46.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 73.1% from the prior year.
Supernus Pharma held $128.4M in cash against $0 in long-term debt as of fiscal year 2025.
Supernus Pharma had 57M shares outstanding in fiscal year 2025. This represents an increase of 3.1% from the prior year.
Margins & Returns
Supernus Pharma's gross margin was 89.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.4 percentage points from the prior year.
Supernus Pharma's operating margin was -8.7% in fiscal year 2025, reflecting core business profitability. This is down 21.0 percentage points from the prior year.
Supernus Pharma's net profit margin was -5.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 16.5 percentage points from the prior year.
Supernus Pharma's ROE was -3.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 10.8 percentage points from the prior year.
Capital Allocation
Supernus Pharma invested $106.2M in research and development in fiscal year 2025. This represents a decrease of 2.4% from the prior year.
Supernus Pharma invested $1.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 84.6% from the prior year.
SUPN Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $207.7M-1.8% | $211.6M+10.1% | $192.1M+16.1% | $165.5M+10.4% | $149.8M-14.0% | $174.2M-0.9% | $175.7M+4.4% | $168.3M |
| Cost of Revenue | $23.4M+1.7% | $23.0M+21.3% | $19.0M+12.7% | $16.8M+6.7% | $15.8M-39.6% | $26.1M+48.4% | $17.6M-1.9% | $17.9M |
| Gross Profit | $184.3M-2.3% | $188.6M+8.9% | $173.1M+16.5% | $148.6M+10.9% | $134.1M-9.5% | $148.1M-6.4% | $158.1M+5.1% | $150.4M |
| R&D Expenses | $39.4M+41.7% | $27.8M-5.2% | $29.4M+32.8% | $22.1M-17.9% | $26.9M-6.0% | $28.6M-1.3% | $29.0M+10.9% | $26.2M |
| SG&A Expenses | $125.2M+2.3% | $122.4M-31.9% | $179.7M+92.1% | $93.6M+4.0% | $89.9M+13.3% | $79.4M+13.8% | $69.8M-18.8% | $85.9M |
| Operating Income | -$8.3M-111.6% | -$3.9M+93.5% | -$60.2M-596.1% | $12.1M+218.4% | -$10.3M-147.9% | $21.4M-47.6% | $40.8M+81.0% | $22.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 |
| Income Tax | -$3.7M-266.9% | $2.2M+117.1% | -$12.8M-120.2% | -$5.8M-197.2% | $6.0M-45.8% | $11.1M+71.5% | $6.4M+0.9% | $6.4M |
| Net Income | -$2.3M+44.8% | -$4.2M+90.8% | -$45.1M-300.5% | $22.5M+290.2% | -$11.8M-177.0% | $15.4M-60.1% | $38.5M+93.3% | $19.9M |
| EPS (Diluted) | $-0.04 | N/A | $-0.80-300.0% | $0.40+290.5% | $-0.21 | N/A | $0.69+91.7% | $0.36 |
SUPN Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.5B+3.3% | $1.5B+2.3% | $1.4B+2.7% | $1.4B+2.6% | $1.3B-1.5% | $1.4B+1.9% | $1.3B+2.0% | $1.3B |
| Current Assets | $731.6M+13.6% | $644.2M+8.5% | $593.9M-19.6% | $738.9M+7.5% | $687.6M+0.2% | $686.1M+7.2% | $640.0M+8.3% | $591.0M |
| Cash & Equivalents | $184.9M+43.9% | $128.4M-15.1% | $151.4M+4.6% | $144.7M+24.9% | $115.8M+67.1% | $69.3M+118.9% | $31.7M-39.2% | $52.1M |
| Inventory | $110.8M-1.5% | $112.5M+5.0% | $107.1M+143.3% | $44.0M-10.9% | $49.4M-9.0% | $54.3M-15.1% | $64.0M-6.1% | $68.2M |
| Accounts Receivable | $182.2M-3.0% | $187.8M+9.7% | $171.3M+21.6% | $140.8M-3.3% | $145.6M+2.5% | $142.1M-2.3% | $145.4M-4.6% | $152.5M |
| Goodwill | $120.7M-3.4% | $124.9M+4.9% | $119.1M+1.8% | $117.0M0.0% | $117.0M0.0% | $117.0M0.0% | $117.0M0.0% | $117.0M |
| Total Liabilities | $423.9M+8.4% | $390.9M+5.6% | $370.1M+16.2% | $318.5M+0.6% | $316.6M-4.7% | $332.3M-1.0% | $335.6M-6.4% | $358.4M |
| Current Liabilities | $373.9M+10.6% | $338.2M+2.3% | $330.6M+15.5% | $286.4M+1.6% | $281.8M-3.6% | $292.4M+0.3% | $291.5M-5.6% | $308.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.1B+1.4% | $1.1B+1.1% | $1.0B-1.3% | $1.1B+3.2% | $1.0B-0.5% | $1.0B+2.8% | $1.0B+5.2% | $957.5M |
| Retained Earnings | $515.6M-0.4% | $517.9M-0.8% | $522.0M-8.0% | $567.1M+4.1% | $544.6M-2.1% | $556.4M+2.8% | $541.1M+7.7% | $502.6M |
SUPN Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $66.5M+234.9% | $19.9M+132.2% | -$61.7M-205.3% | $58.5M+91.3% | $30.6M-31.1% | $44.4M-17.0% | $53.5M+50.2% | $35.6M |
| Capital Expenditures | $0-100.0% | $427K+231.0% | $129K-71.6% | $455K+39.1% | $327K+53.5% | $213K+6.5% | $200K+212.5% | $64K |
| Free Cash Flow | $66.5M+242.3% | $19.4M+131.5% | -$61.8M-206.4% | $58.1M+91.9% | $30.3M-31.5% | $44.2M-17.1% | $53.3M+49.9% | $35.6M |
| Investing Cash Flow | -$19.2M+62.5% | -$51.3M-205.3% | $48.7M+259.1% | -$30.6M-182.0% | $37.3M+395.3% | -$12.6M+83.6% | -$77.0M-58.5% | -$48.6M |
| Financing Cash Flow | $9.1M+6.9% | $8.5M-59.5% | $21.1M+2153.3% | $935K+104.4% | -$21.4M-463.3% | $5.9M+91.5% | $3.1M+85.5% | $1.7M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SUPN Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.7%-0.4pp | 89.1%-1.0pp | 90.1%+0.3pp | 89.8%+0.3pp | 89.5%+4.5pp | 85.0%-5.0pp | 90.0%+0.6pp | 89.4% |
| Operating Margin | -4.0%-2.1pp | -1.9%+29.5pp | -31.4%-38.7pp | 7.3%+14.2pp | -6.9%-19.1pp | 12.3%-11.0pp | 23.3%+9.8pp | 13.4% |
| Net Margin | -1.1%+0.9pp | -2.0%+21.5pp | -23.5%-37.1pp | 13.6%+21.5pp | -7.9%-16.7pp | 8.8%-13.1pp | 21.9%+10.1pp | 11.8% |
| Return on Equity | -0.2%+0.2pp | -0.4%+3.9pp | -4.3%-6.4pp | 2.1%+3.3pp | -1.1%-2.6pp | 1.5%-2.3pp | 3.8%+1.7pp | 2.1% |
| Return on Assets | -0.1%+0.1pp | -0.3%+2.9pp | -3.2%-4.8pp | 1.6%+2.5pp | -0.9%-2.0pp | 1.1%-1.8pp | 2.9%+1.4pp | 1.5% |
| Current Ratio | 1.96+0.1 | 1.90+0.1 | 1.80-0.8 | 2.58+0.1 | 2.44+0.1 | 2.35+0.2 | 2.20+0.3 | 1.91 |
| Debt-to-Equity | 0.39+0.0 | 0.37+0.0 | 0.35+0.1 | 0.300.0 | 0.31-0.0 | 0.32-0.0 | 0.33-0.0 | 0.37 |
| FCF Margin | 32.0%+22.8pp | 9.2%+41.4pp | -32.2%-67.3pp | 35.1%+14.9pp | 20.2%-5.2pp | 25.4%-5.0pp | 30.3%+9.2pp | 21.1% |
Similar Companies
Frequently Asked Questions
What is Supernus Pharma's annual revenue?
Supernus Pharma (SUPN) reported $719.0M in total revenue for fiscal year 2025. This represents a 8.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Supernus Pharma's revenue growing?
Supernus Pharma (SUPN) revenue grew by 8.6% year-over-year, from $661.8M to $719.0M in fiscal year 2025.
Is Supernus Pharma profitable?
No, Supernus Pharma (SUPN) reported a net income of -$38.6M in fiscal year 2025, with a net profit margin of -5.4%.
What is Supernus Pharma's EBITDA?
Supernus Pharma (SUPN) had EBITDA of $29.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Supernus Pharma's gross margin?
Supernus Pharma (SUPN) had a gross margin of 89.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Supernus Pharma's operating margin?
Supernus Pharma (SUPN) had an operating margin of -8.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Supernus Pharma's net profit margin?
Supernus Pharma (SUPN) had a net profit margin of -5.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Supernus Pharma's return on equity (ROE)?
Supernus Pharma (SUPN) has a return on equity of -3.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Supernus Pharma's free cash flow?
Supernus Pharma (SUPN) generated $46.0M in free cash flow during fiscal year 2025. This represents a -73.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Supernus Pharma's operating cash flow?
Supernus Pharma (SUPN) generated $47.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Supernus Pharma's total assets?
Supernus Pharma (SUPN) had $1.5B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Supernus Pharma's capital expenditures?
Supernus Pharma (SUPN) invested $1.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Supernus Pharma spend on research and development?
Supernus Pharma (SUPN) invested $106.2M in research and development during fiscal year 2025.
What is Supernus Pharma's current ratio?
Supernus Pharma (SUPN) had a current ratio of 1.90 as of fiscal year 2025, which is generally considered healthy.
What is Supernus Pharma's debt-to-equity ratio?
Supernus Pharma (SUPN) had a debt-to-equity ratio of 0.37 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Supernus Pharma's return on assets (ROA)?
Supernus Pharma (SUPN) had a return on assets of -2.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Supernus Pharma's Altman Z-Score?
Supernus Pharma (SUPN) has an Altman Z-Score of 5.45, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Supernus Pharma's Piotroski F-Score?
Supernus Pharma (SUPN) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Supernus Pharma's earnings high quality?
Supernus Pharma (SUPN) has an earnings quality ratio of -1.23x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Supernus Pharma?
Supernus Pharma (SUPN) scores 54 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.